Clinical trials
AFP Gastric or Gastroesophageal Junction Adenocarcinoma clinical trials
Below are recruiting afp gastric or gastroesophageal junction adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 267 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06985602RecruitingPhase 2
Adebrelimab with Chemo and Radiation for Stomach Cancer
This trial tests a drug called adebrelimab along with chemotherapy and radiation before surgery for stomach or gastroesophageal junction cancer that has spread locally or has limited spread. It aims to see if this combination can help make the tumor removable and improve outcomes.
Nanjing, ProvinceAges 18–80 - NCT06791538Recruiting
Robotic vs. laparoscopic surgery for advanced stomach cancer
This trial compares robotic-assisted surgery to standard laparoscopic surgery for locally advanced stomach cancer. It aims to see which approach offers better outcomes and recovery for patients.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06808971RecruitingPhase 2
Perioperative drug combo for advanced stomach cancer
This study tests a combination of four drugs given before and after surgery for a type of stomach or throat-stomach cancer that can be removed. The drugs are adebrelimab (immunotherapy), nab-paclitaxel, oxaliplatin, and tegafur. The goal is to see if this combination works better than standard treatments.
BeijingAges 18–75 - NCT06131840RecruitingPhase 1
Study of SGN-CEACAM5C for advanced solid tumors
This trial tests a new drug called SGN-CEACAM5C in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein on cancer cells to try to stop them from growing.
Phoenix, ArizonaAges 18 years+ - NCT05671822RecruitingPhase 2
Study of targeted drugs for HER2-positive advanced stomach cancer
This Phase 2 trial tests whether SHR-A1811—given with other medicines—works safely and effectively for people with advanced stomach or gastroesophageal junction cancer that has high HER2. It may help shrink tumors or slow cancer growth, especially if previous treatment didn’t work.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05187182RecruitingPhase 1
Testing a new cancer drug with FOLFOX and immune therapy
This Phase 1 study tests CA-4948 given with standard chemotherapy (FOLFOX) and an immune therapy (an immune checkpoint inhibitor, similar to PD-1). It’s for people with advanced stomach or esophageal cancer that can’t be removed by surgery, to see how well the treatment works and whether it’s safe.
St Louis, MissouriAges 18 years+ - NCT05918094RecruitingPhase 3
Testing new chemo plan plus immunotherapy for stomach cancer
This phase 3 study compares two versions of a first-time treatment for HER2-negative advanced stomach or gastroesophageal cancer, both including immunotherapy (sintilimab). It looks for a safer or more effective way to slow cancer growth or improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT07800754Recruiting
Stomach and esophageal cancer care in Greece
This study is for people with stomach or esophageal cancer in Greece. It is not a treatment study; it simply looks at how patients are diagnosed and treated in regular practice, so participating won't change your care.
AlexandroupoliAges 18–130 - NCT05370144Recruiting
Pre-surgery chemotherapy and radiation for esophagus cancer
This study tests a new pre-surgery treatment plan that combines chemotherapy with focused, shorter-course radiation for esophagus or stomach-where-it-meets-the-esophagus (GEJ) adenocarcinoma. The goal is to shrink the tumor before surgery and improve treatment outcomes.
Calgary, AlbertaAges 18–80 - NCT04510129Recruiting
Cancer biospecimen collection study for immunotherapy patients
This study collects samples (like tissue biopsies and imaging information) from people with certain cancers who are starting anti–PD-1/PD-L1 immunotherapy. It helps researchers gather material to study how these treatments work.
San Francisco, CaliforniaAges 18 years+ - NCT06300879Recruiting
New surgery technique for upper stomach or junction cancer
This study tests a new surgical technique for removing cancer in the upper stomach or where the stomach meets the esophagus. It aims to see if this technique is safe and effective for people with early-stage adenocarcinoma who haven't had other cancer treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07110571RecruitingPhase 2
Combination therapy study for untreated stomach or GEJ cancer
This trial tests a combination of adebrelimab (an immunotherapy) with either two other experimental drugs (SHR-A1811 or SHR-A1904) plus chemotherapy, or another drug (SHR-8068), as a first treatment for gastric or gastroesophageal junction adenocarcinoma. It aims to find if these combos work better than standard care.
Shijiazhuang, HebeiAges 18–70 - NCT06929949Recruiting
Best Reconnection Method After Upper Stomach Surgery
This study compares different ways of reconnecting the digestive tract after surgery to remove the upper part of the stomach. It aims to see which method leads to a better quality of life for people with early-stage stomach or esophageal junction cancer.
Changchun, JilinAges 18–75 - NCT06329973RecruitingPhase 1/Phase 2
Fruquintinib, sintilimab, and chemo for stomach cancer
This trial tests a combination of three drugs (fruquintinib, sintilimab, and CAPEOX chemotherapy) as a first treatment for advanced stomach or gastroesophageal cancer. The goal is to see if this combination helps slow or shrink the tumor.
Zhengzhou, HenanAges 18–75 - NCT06793917RecruitingPhase 3
Immunotherapy plus chemo vs. chemo alone for advanced stomach cancer
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
Fuzhou, FujianAges 18–70 - NCT06265285RecruitingPhase 2
Nivolumab at home vs. clinic for cancer treatment
This study compares giving the immunotherapy drug nivolumab as a shot under the skin at home versus in the clinic. It is for people with certain cancers who are already taking or starting nivolumab.
Jacksonville, FloridaAges 18 years+ - NCT04656041RecruitingPhase 2
Test chemo with radiation for gastroesophageal cancer
This Phase 2 study tests a combination of chemotherapy (5-FU/leucovorin plus irinotecan and oxaliplatin) together with radiation for certain types of esophagus/stomach-junction cancer. It may help shrink tumors and control cancer that is locally advanced but not spread to distant organs.
Boston, MassachusettsAges 18 years+ - NCT05872295RecruitingPhase 1
Study drug for HER2-positive advanced cancers
This Phase 1 trial tests IKS014 to see how safe it is and how well it works in advanced solid tumors that have HER2. You may be eligible if your tumor is HER2-positive (including certain “low HER2” types) and your body’s blood counts and organ function are strong enough.
Newport Beach, CaliforniaAges 18 years+ - NCT05563766RecruitingPhase 2
Itraconazole with standard treatment for esophageal cancer
This trial tests whether adding the antifungal drug itraconazole to the usual chemotherapy and radiation before surgery can improve the chance of no cancer cells remaining at surgery. It is for patients with esophageal or gastroesophageal junction cancer that can be surgically removed.
Palo Alto, CaliforniaAges 18 years+ - NCT03539822RecruitingPhase 1/Phase 2
Cabozantinib and immunotherapy for advanced stomach or bowel cancers
This early-phase study tests a combination of anti-cancer pills and immune-based treatment for people with advanced stomach, esophagus, colorectal, or liver cancer. It aims to shrink tumors and see how safe the treatment is, including whether biopsy testing can help guide future care.
Westwood, KansasAges 18 years+ - NCT03526835RecruitingPhase 1/Phase 2
Study of MCLA-158 for advanced solid tumors
This trial tests a new experimental drug called MCLA-158 (petosemtamab) for people with advanced solid tumors, especially head and neck cancer or colorectal cancer, that have not responded to standard treatments. The study aims to see if this drug can shrink tumors or slow their growth.
La Jolla, CaliforniaAges 18 years+ - NCT06044311RecruitingPhase 2
Vactosertib with chemo and radiation for esophageal cancer
This trial tests whether adding a new drug called vactosertib to standard chemotherapy and radiation before surgery can help treat esophageal adenocarcinoma. It aims to see if the combination is safe and effective for patients with stage II or III disease.
Cleveland, OhioAges 18 years+ - NCT06846346RecruitingPhase 2
Testing Ivonescimab with Chemo for Advanced Stomach Cancer
This trial tests a new immunotherapy drug called ivonescimab given together with standard chemotherapy for advanced stomach cancer. It may help your immune system fight the cancer more effectively.
LyonAges 18 years+ - NCT07334431RecruitingPhase 1/Phase 2
A trial of fruquintinib, trastuzumab, and chemo for HER2-positive stomach cancer
This study tests a combination of three drugs (fruquintinib, trastuzumab, and XELOX chemotherapy) as the first treatment for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The goal is to see if this combination is safe and effective for shrinking tumors.
Zhengzhou, HenanAges 18–75
Hear when a new AFP Gastric or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for afp gastric or gastroesophageal junction adenocarcinoma?
- Yes. Clin2 currently lists 267 recruiting afp gastric or gastroesophageal junction adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a afp gastric or gastroesophageal junction adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a afp gastric or gastroesophageal junction adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Gastric / Gastroesophageal Junction Adenocarcinoma
- Gastric or Gastroesophageal Junction Adenocarcinoma
- Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
- Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Metastatic Gastroesophageal Junction Adenocarcinoma
- Gastroesophageal Junction (GEJ) Adenocarcinoma
- Advanced Gastroesophageal Junction Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.